AzTrials
AzTrials

Cesarean SectionPhase 3NCT00811603

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

A Phase 3 study testing Cefazolin (Timing of Antibiotic Prophylaxis) in people with Cesarean Section and Infection, run by MemorialCare at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the rates of maternal and neonatal infectious morbidity in gravid patients undergoing cesarean delivery. Specifically, the investigators are examining whether the timing of antibiotic administration has any effect on rates of maternal and neonatal infections, neonatal sepsis… Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
Conditions the study is for
Cesarean Section, Infection
What is being tested?
Cefazolin (Timing of Antibiotic Prophylaxis)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
2 sitesUnited States
Study dates
Aug 2008to Sep 2009
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients 18 years of age or older
  • Any patient at term (>37 weeks gestation) undergoing a scheduled cesarean delivery

Who cannot join

  • Women younger than 18 years
  • Patients who are febrile during or prior to screening or with a diagnosis of clinical suspicion of endometritis (with or without maternal fever)
  • Patients who present with ruptured membranes
  • Known fetal malformations
  • Contraindications to cefazolin administration (known anaphylactic reaction to penicillins or known cephalosporin allergy)
  • Any exposure to antibiotics in one week prior to cesarean delivery
  • Obstetrical indication for an emergent cesarean delivery
  • Patients taking glucocorticoids or other immunosuppressant therapy

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Long Beach Memorial Medical Center

    Long Beach, California, 90806

  • University of California, Irvine Medical Center

    Orange, California, 92868

Other trials in United States

About this study

Official title: Optimal Timing for Antibiotic Prophylaxis for Elective Cesarean Delivery in Term Gestations: A Randomized, Controlled Trial Comparing Cefazolin Administration Prior to Skin Incision Versus Following Cord Clamping

The purpose of this study is to evaluate the rates of maternal and neonatal infectious morbidity in gravid patients undergoing cesarean delivery. Specifically, the investigators are examining whether the timing of antibiotic administration has any effect on rates of maternal and neonatal infections, neonatal sepsis work-up and length of hospital stay.

Read the detailed description

Nearly fifty years have passed since Burke et al first demonstrated in animal model the reduction of infection rates in contaminated skin incisions with administration of antibiotic prophylaxis. Further research in the area confirmed the benefit of prophylactic antibiotics in human subjects. Patients who develop surgical infections are 60% more likely to spend time in intensive care unit, five times more likely to be readmitted to the hospital, and have twice the mortality rate compared to patients without infections. As a result the potential health care costs are staggering. Recently, the National Surgical Infection Prevention Project endorsed the recommendation that antibiotic prophylaxis should be administered within 60 minutes before skin incision. This model has been universally accepted in all surgical fields with the exception of obstetrics.

Cesarean delivery has been shown to be the most important risk factor for post-partum maternal infection. In fact, women undergoing cesarean delivery have a five to twenty-fold greater risk for developing infection compared to those undergoing vaginal delivery. Recent review by Cochrane Database found that there is an inconsistent and variable application of current recommendations in regard to appropriate timing, administration and choice of drug used for antibiotic prophylaxis at the time of cesarean delivery. Cesarean section holds a unique position amongst all the surgical procedures as being the only one where prophylactic antibiotics are administered after the incision is made. The concern for intrapartum fetal exposure of prophylactic antibiotics suppressing microbial growth and thereby masking neonatal sepsis led to a tradition of delaying antibiotic administration until umbilical cord clamping. While a recent study demonstrated that antibiotic levels do indeed reach therapeutic levels within cord blood very quickly after administration to the mother, no adverse outcomes to the newborns have ever been documented as a result. To date only four studies have looked at the timing of prophylactic administration at the time of cesarean section.

In 1982, Cunningham et al randomized 642 women "at high risk for infection following cesarean delivery" to receiving antibiotics before or after cord clamping. The authors demonstrated that there was no difference between uterine infection rates between the two groups. While significantly more infants exposed to intrapartum maternal antibiotics were evaluated for sepsis, there were no cases of neonatal bacteremia in either group. However, it should be noted that the pediatricians in this study were fully aware of whether antibiotics had been given before or after cord clamping. Wax et al revisited the issue by randomizing 90 consecutive term women in labor to receiving cefazolin preoperatively or after skin incision. While the authors failed to show any statistical significance between two groups, this study was clearly underpowered as only four cases achieved primary outcomes. Furthermore, the authors failed to demonstrate a significant increase is suspected sepsis in newborns whose mothers received cefazolin preoperatively. In 2005, Thigpen et al once again demonstrated that there was no disadvantage to the infant in regard to infectious morbidity. In addition, there was no difference in maternal infectious morbidity regardless of when antibiotics were administered. However, the results are questionable as nearly a quarter of all subjects received penicillin for GBS prophylaxis. Finally, Sullivan included 357 women in a well designed randomized, double-blinded study that demonstrated a statistically significant reduction in maternal infectious morbidity when the antibiotics where administered preoperatively. Not only was there no difference between two groups in regard to neonatal infection, but there was actually significantly fewer NICU admission days in preoperative antibiotic group.

Despite the evidence that preoperative prophylactic antibiotics pose no harm to the fetus, obstetrics has been slow to adopt this practice. It is no wonder that cesarean infection rates have been shown to be considerably higher than comparable surgical procedures. While the evidence clearly demonstrates the absence of negative impact of preoperative antibiotics on neonatal outcomes, a contemporary scientific evaluation of the reduction in maternal infectious morbidity is warranted before adopting this practice on universal basis.

Being tested
Cefazolin (Timing of Antibiotic Prophylaxis)
Keywords
Antibiotic, Prophylaxis, Cesarean, Infection, Antibiotic prophylaxis
Medical subject headings
Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cefazolin (Timing of Antibiotic Prophylaxis)Drug

    Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord

Study groups in NCT00811603
Study groupRoleWhat they receive
1Active comparatorPatients who receive antibiotic prophylaxis after clamping of the umbilical cord
Receives: Drug: Cefazolin (Timing of Antibiotic Prophylaxis)
2ExperimentalPatients who receive antibiotic prophylaxis prior to skin incision
Receives: Drug: Cefazolin (Timing of Antibiotic Prophylaxis)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping

    Measured: 6 weeks

Secondary outcomes (1)
  1. To assess incidence of neonatal infectious morbidity (i.e. rates of sepsis work-up, confirmed sepsis, and length of hospital stay) between two study arms

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2008 (estimated)
  2. Study startAug 2008
  3. Primary completionJun 2009
  4. Study completionSep 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00811603
Sponsor's protocol ID
474-07
Status last verified
Sep 2009
First submitted
17 Dec 2008
Last updated
18 Sep 2009
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Cefazolin (Timing of Antibiotic Prophylaxis) in people with Cesarean Section and Infection, run by MemorialCare at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Sep 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To assess the rates of maternal infectious morbidity with preoperative administration of antibiotics when compared to antibiotic prophylaxis given following umbilical cord clamping (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2009.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in